nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—osteoarthritis—Prednisone—prostate cancer	0.271	1	CpDpCtD
Meloxicam—CYP3A4—prostate cancer	0.0883	0.505	CbGaD
Meloxicam—PTGS2—prostate cancer	0.0865	0.495	CbGaD
Meloxicam—ABCC4—Conjugated Estrogens—prostate cancer	0.0377	0.115	CbGbCtD
Meloxicam—CYP2C8—Nilutamide—prostate cancer	0.0276	0.0843	CbGbCtD
Meloxicam—CYP2C8—Abiraterone—prostate cancer	0.0228	0.0698	CbGbCtD
Meloxicam—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0213	0.0651	CbGbCtD
Meloxicam—CYP2C9—Nilutamide—prostate cancer	0.0192	0.0588	CbGbCtD
Meloxicam—CYP2C9—Bicalutamide—prostate cancer	0.0192	0.0588	CbGbCtD
Meloxicam—CYP2C8—Cabazitaxel—prostate cancer	0.0169	0.0517	CbGbCtD
Meloxicam—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0147	0.045	CbGbCtD
Meloxicam—PTGS2—Etoposide—prostate cancer	0.0127	0.0389	CbGbCtD
Meloxicam—CYP2C9—Estrone—prostate cancer	0.0115	0.0352	CbGbCtD
Meloxicam—CYP3A4—Bicalutamide—prostate cancer	0.0112	0.0342	CbGbCtD
Meloxicam—PTGS1—Etoposide—prostate cancer	0.0107	0.0328	CbGbCtD
Meloxicam—CYP3A4—Estramustine—prostate cancer	0.0104	0.0318	CbGbCtD
Meloxicam—CYP2C8—Estradiol—prostate cancer	0.00948	0.029	CbGbCtD
Meloxicam—CYP3A4—Abiraterone—prostate cancer	0.00926	0.0283	CbGbCtD
Meloxicam—CYP3A4—Flutamide—prostate cancer	0.00926	0.0283	CbGbCtD
Meloxicam—CYP2C9—Capecitabine—prostate cancer	0.00872	0.0267	CbGbCtD
Meloxicam—CYP3A4—Cabazitaxel—prostate cancer	0.00685	0.021	CbGbCtD
Meloxicam—CYP3A4—Estrone—prostate cancer	0.00669	0.0205	CbGbCtD
Meloxicam—CYP2C9—Estradiol—prostate cancer	0.00661	0.0202	CbGbCtD
Meloxicam—CYP2C8—Etoposide—prostate cancer	0.00619	0.0189	CbGbCtD
Meloxicam—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00597	0.0183	CbGbCtD
Meloxicam—CYP3A4—Conjugated Estrogens—prostate cancer	0.00438	0.0134	CbGbCtD
Meloxicam—CYP3A4—Mitoxantrone—prostate cancer	0.00398	0.0122	CbGbCtD
Meloxicam—CYP3A4—Estradiol—prostate cancer	0.00384	0.0118	CbGbCtD
Meloxicam—CYP3A4—Prednisone—prostate cancer	0.00331	0.0101	CbGbCtD
Meloxicam—CYP3A4—Etoposide—prostate cancer	0.00251	0.00768	CbGbCtD
Meloxicam—CYP3A4—Docetaxel—prostate cancer	0.0023	0.00703	CbGbCtD
Meloxicam—CYP3A4—Doxorubicin—prostate cancer	0.00171	0.00524	CbGbCtD
Meloxicam—CYP2C9—urine—prostate cancer	0.00155	0.0965	CbGeAlD
Meloxicam—PGD—prostate gland—prostate cancer	0.00122	0.0755	CbGeAlD
Meloxicam—CYP3A4—urine—prostate cancer	0.00118	0.0736	CbGeAlD
Meloxicam—PGD—seminal vesicle—prostate cancer	0.00103	0.0639	CbGeAlD
Meloxicam—ABCC4—prostate gland—prostate cancer	0.000865	0.0537	CbGeAlD
Meloxicam—PGD—renal system—prostate cancer	0.000829	0.0515	CbGeAlD
Meloxicam—PGD—urethra—prostate cancer	0.000814	0.0506	CbGeAlD
Meloxicam—PGD—bone marrow—prostate cancer	0.000627	0.0389	CbGeAlD
Meloxicam—ABCC4—renal system—prostate cancer	0.00059	0.0366	CbGeAlD
Meloxicam—PGD—testis—prostate cancer	0.000536	0.0333	CbGeAlD
Meloxicam—PTGS1—prostate gland—prostate cancer	0.000509	0.0316	CbGeAlD
Meloxicam—PTGS2—prostate gland—prostate cancer	0.000487	0.0302	CbGeAlD
Meloxicam—ABCC4—bone marrow—prostate cancer	0.000446	0.0277	CbGeAlD
Meloxicam—PTGS1—seminal vesicle—prostate cancer	0.000431	0.0268	CbGeAlD
Meloxicam—CYP2C8—renal system—prostate cancer	0.000428	0.0266	CbGeAlD
Meloxicam—PTGS2—seminal vesicle—prostate cancer	0.000412	0.0256	CbGeAlD
Meloxicam—PGD—lymph node—prostate cancer	0.000388	0.0241	CbGeAlD
Meloxicam—ABCC4—testis—prostate cancer	0.000381	0.0237	CbGeAlD
Meloxicam—PTGS1—epithelium—prostate cancer	0.000374	0.0232	CbGeAlD
Meloxicam—PTGS2—epithelium—prostate cancer	0.000358	0.0222	CbGeAlD
Meloxicam—PTGS1—renal system—prostate cancer	0.000347	0.0216	CbGeAlD
Meloxicam—PTGS2—renal system—prostate cancer	0.000332	0.0206	CbGeAlD
Meloxicam—Lornoxicam—PTGS2—prostate cancer	0.000331	0.41	CrCbGaD
Meloxicam—PTGS2—urethra—prostate cancer	0.000326	0.0202	CbGeAlD
Meloxicam—Tenoxicam—PTGS2—prostate cancer	0.000295	0.365	CrCbGaD
Meloxicam—CYP3A4—renal system—prostate cancer	0.00029	0.018	CbGeAlD
Meloxicam—CYP2C8—testis—prostate cancer	0.000277	0.0172	CbGeAlD
Meloxicam—ABCC4—lymph node—prostate cancer	0.000276	0.0172	CbGeAlD
Meloxicam—PTGS2—bone marrow—prostate cancer	0.000251	0.0156	CbGeAlD
Meloxicam—PTGS1—testis—prostate cancer	0.000224	0.0139	CbGeAlD
Meloxicam—Piroxicam—PTGS2—prostate cancer	0.000182	0.226	CrCbGaD
Meloxicam—PTGS1—lymph node—prostate cancer	0.000163	0.0101	CbGeAlD
Meloxicam—PTGS2—lymph node—prostate cancer	0.000155	0.00965	CbGeAlD
Meloxicam—Paraesthesia—Docetaxel—prostate cancer	2.55e-05	0.000187	CcSEcCtD
Meloxicam—Erythema multiforme—Epirubicin—prostate cancer	2.55e-05	0.000187	CcSEcCtD
Meloxicam—Anxiety—Prednisone—prostate cancer	2.55e-05	0.000187	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.54e-05	0.000186	CcSEcCtD
Meloxicam—Dyspnoea—Docetaxel—prostate cancer	2.54e-05	0.000186	CcSEcCtD
Meloxicam—Somnolence—Docetaxel—prostate cancer	2.53e-05	0.000185	CcSEcCtD
Meloxicam—Discomfort—Prednisone—prostate cancer	2.53e-05	0.000185	CcSEcCtD
Meloxicam—Eye disorder—Epirubicin—prostate cancer	2.52e-05	0.000185	CcSEcCtD
Meloxicam—Hypersensitivity—Etoposide—prostate cancer	2.52e-05	0.000185	CcSEcCtD
Meloxicam—Tinnitus—Epirubicin—prostate cancer	2.52e-05	0.000184	CcSEcCtD
Meloxicam—Haemoglobin—Doxorubicin—prostate cancer	2.51e-05	0.000184	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.51e-05	0.000184	CcSEcCtD
Meloxicam—Flushing—Epirubicin—prostate cancer	2.51e-05	0.000183	CcSEcCtD
Meloxicam—Cardiac disorder—Epirubicin—prostate cancer	2.51e-05	0.000183	CcSEcCtD
Meloxicam—Rhinitis—Doxorubicin—prostate cancer	2.5e-05	0.000183	CcSEcCtD
Meloxicam—Dyspepsia—Docetaxel—prostate cancer	2.5e-05	0.000183	CcSEcCtD
Meloxicam—Haemorrhage—Doxorubicin—prostate cancer	2.5e-05	0.000183	CcSEcCtD
Meloxicam—Hepatitis—Doxorubicin—prostate cancer	2.5e-05	0.000183	CcSEcCtD
Meloxicam—Insomnia—Capecitabine—prostate cancer	2.49e-05	0.000182	CcSEcCtD
Meloxicam—Pharyngitis—Doxorubicin—prostate cancer	2.48e-05	0.000181	CcSEcCtD
Meloxicam—Paraesthesia—Capecitabine—prostate cancer	2.47e-05	0.000181	CcSEcCtD
Meloxicam—Decreased appetite—Docetaxel—prostate cancer	2.47e-05	0.000181	CcSEcCtD
Meloxicam—Urinary tract disorder—Doxorubicin—prostate cancer	2.47e-05	0.000181	CcSEcCtD
Meloxicam—Oedema peripheral—Doxorubicin—prostate cancer	2.46e-05	0.00018	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Docetaxel—prostate cancer	2.46e-05	0.00018	CcSEcCtD
Meloxicam—Asthenia—Etoposide—prostate cancer	2.46e-05	0.00018	CcSEcCtD
Meloxicam—Connective tissue disorder—Doxorubicin—prostate cancer	2.46e-05	0.00018	CcSEcCtD
Meloxicam—Dyspnoea—Capecitabine—prostate cancer	2.45e-05	0.00018	CcSEcCtD
Meloxicam—Oedema—Prednisone—prostate cancer	2.45e-05	0.00018	CcSEcCtD
Meloxicam—Anaphylactic shock—Prednisone—prostate cancer	2.45e-05	0.00018	CcSEcCtD
Meloxicam—Fatigue—Docetaxel—prostate cancer	2.45e-05	0.000179	CcSEcCtD
Meloxicam—Angiopathy—Epirubicin—prostate cancer	2.45e-05	0.000179	CcSEcCtD
Meloxicam—Urethral disorder—Doxorubicin—prostate cancer	2.45e-05	0.000179	CcSEcCtD
Meloxicam—Nausea—Mitoxantrone—prostate cancer	2.44e-05	0.000179	CcSEcCtD
Meloxicam—Immune system disorder—Epirubicin—prostate cancer	2.44e-05	0.000178	CcSEcCtD
Meloxicam—Infection—Prednisone—prostate cancer	2.44e-05	0.000178	CcSEcCtD
Meloxicam—Mediastinal disorder—Epirubicin—prostate cancer	2.43e-05	0.000178	CcSEcCtD
Meloxicam—Pain—Docetaxel—prostate cancer	2.43e-05	0.000178	CcSEcCtD
Meloxicam—Constipation—Docetaxel—prostate cancer	2.43e-05	0.000178	CcSEcCtD
Meloxicam—Dyspepsia—Capecitabine—prostate cancer	2.42e-05	0.000177	CcSEcCtD
Meloxicam—Pruritus—Etoposide—prostate cancer	2.42e-05	0.000177	CcSEcCtD
Meloxicam—Shock—Prednisone—prostate cancer	2.41e-05	0.000177	CcSEcCtD
Meloxicam—Arrhythmia—Epirubicin—prostate cancer	2.41e-05	0.000177	CcSEcCtD
Meloxicam—Visual impairment—Doxorubicin—prostate cancer	2.41e-05	0.000176	CcSEcCtD
Meloxicam—Nervous system disorder—Prednisone—prostate cancer	2.41e-05	0.000176	CcSEcCtD
Meloxicam—Tachycardia—Prednisone—prostate cancer	2.39e-05	0.000175	CcSEcCtD
Meloxicam—Decreased appetite—Capecitabine—prostate cancer	2.39e-05	0.000175	CcSEcCtD
Meloxicam—Alopecia—Epirubicin—prostate cancer	2.39e-05	0.000175	CcSEcCtD
Meloxicam—Skin disorder—Prednisone—prostate cancer	2.38e-05	0.000174	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Capecitabine—prostate cancer	2.38e-05	0.000174	CcSEcCtD
Meloxicam—Fatigue—Capecitabine—prostate cancer	2.37e-05	0.000174	CcSEcCtD
Meloxicam—Hyperhidrosis—Prednisone—prostate cancer	2.37e-05	0.000174	CcSEcCtD
Meloxicam—Mental disorder—Epirubicin—prostate cancer	2.37e-05	0.000173	CcSEcCtD
Meloxicam—Erythema multiforme—Doxorubicin—prostate cancer	2.36e-05	0.000173	CcSEcCtD
Meloxicam—Pain—Capecitabine—prostate cancer	2.35e-05	0.000172	CcSEcCtD
Meloxicam—Constipation—Capecitabine—prostate cancer	2.35e-05	0.000172	CcSEcCtD
Meloxicam—Erythema—Epirubicin—prostate cancer	2.35e-05	0.000172	CcSEcCtD
Meloxicam—Malnutrition—Epirubicin—prostate cancer	2.35e-05	0.000172	CcSEcCtD
Meloxicam—Feeling abnormal—Docetaxel—prostate cancer	2.34e-05	0.000172	CcSEcCtD
Meloxicam—Diarrhoea—Etoposide—prostate cancer	2.34e-05	0.000171	CcSEcCtD
Meloxicam—Eye disorder—Doxorubicin—prostate cancer	2.33e-05	0.000171	CcSEcCtD
Meloxicam—Tinnitus—Doxorubicin—prostate cancer	2.33e-05	0.00017	CcSEcCtD
Meloxicam—Gastrointestinal pain—Docetaxel—prostate cancer	2.33e-05	0.00017	CcSEcCtD
Meloxicam—Flushing—Doxorubicin—prostate cancer	2.32e-05	0.00017	CcSEcCtD
Meloxicam—Cardiac disorder—Doxorubicin—prostate cancer	2.32e-05	0.00017	CcSEcCtD
Meloxicam—Flatulence—Epirubicin—prostate cancer	2.32e-05	0.00017	CcSEcCtD
Meloxicam—Tension—Epirubicin—prostate cancer	2.31e-05	0.000169	CcSEcCtD
Meloxicam—Dysgeusia—Epirubicin—prostate cancer	2.3e-05	0.000168	CcSEcCtD
Meloxicam—Nervousness—Epirubicin—prostate cancer	2.28e-05	0.000167	CcSEcCtD
Meloxicam—Back pain—Epirubicin—prostate cancer	2.27e-05	0.000166	CcSEcCtD
Meloxicam—Feeling abnormal—Capecitabine—prostate cancer	2.27e-05	0.000166	CcSEcCtD
Meloxicam—Angiopathy—Doxorubicin—prostate cancer	2.27e-05	0.000166	CcSEcCtD
Meloxicam—Dizziness—Etoposide—prostate cancer	2.26e-05	0.000166	CcSEcCtD
Meloxicam—Muscle spasms—Epirubicin—prostate cancer	2.26e-05	0.000165	CcSEcCtD
Meloxicam—Immune system disorder—Doxorubicin—prostate cancer	2.26e-05	0.000165	CcSEcCtD
Meloxicam—Gastrointestinal pain—Capecitabine—prostate cancer	2.25e-05	0.000165	CcSEcCtD
Meloxicam—Mediastinal disorder—Doxorubicin—prostate cancer	2.25e-05	0.000165	CcSEcCtD
Meloxicam—Body temperature increased—Docetaxel—prostate cancer	2.25e-05	0.000165	CcSEcCtD
Meloxicam—Abdominal pain—Docetaxel—prostate cancer	2.25e-05	0.000165	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Prednisone—prostate cancer	2.23e-05	0.000164	CcSEcCtD
Meloxicam—Arrhythmia—Doxorubicin—prostate cancer	2.23e-05	0.000163	CcSEcCtD
Meloxicam—Insomnia—Prednisone—prostate cancer	2.22e-05	0.000162	CcSEcCtD
Meloxicam—Vision blurred—Epirubicin—prostate cancer	2.22e-05	0.000162	CcSEcCtD
Meloxicam—Alopecia—Doxorubicin—prostate cancer	2.21e-05	0.000162	CcSEcCtD
Meloxicam—Paraesthesia—Prednisone—prostate cancer	2.2e-05	0.000161	CcSEcCtD
Meloxicam—Mental disorder—Doxorubicin—prostate cancer	2.19e-05	0.00016	CcSEcCtD
Meloxicam—Urticaria—Capecitabine—prostate cancer	2.19e-05	0.00016	CcSEcCtD
Meloxicam—Ill-defined disorder—Epirubicin—prostate cancer	2.18e-05	0.00016	CcSEcCtD
Meloxicam—Body temperature increased—Capecitabine—prostate cancer	2.18e-05	0.000159	CcSEcCtD
Meloxicam—Abdominal pain—Capecitabine—prostate cancer	2.18e-05	0.000159	CcSEcCtD
Meloxicam—Vomiting—Etoposide—prostate cancer	2.18e-05	0.000159	CcSEcCtD
Meloxicam—Erythema—Doxorubicin—prostate cancer	2.17e-05	0.000159	CcSEcCtD
Meloxicam—Malnutrition—Doxorubicin—prostate cancer	2.17e-05	0.000159	CcSEcCtD
Meloxicam—Anaemia—Epirubicin—prostate cancer	2.17e-05	0.000159	CcSEcCtD
Meloxicam—Dyspepsia—Prednisone—prostate cancer	2.16e-05	0.000158	CcSEcCtD
Meloxicam—Rash—Etoposide—prostate cancer	2.16e-05	0.000158	CcSEcCtD
Meloxicam—Dermatitis—Etoposide—prostate cancer	2.16e-05	0.000158	CcSEcCtD
Meloxicam—Headache—Etoposide—prostate cancer	2.14e-05	0.000157	CcSEcCtD
Meloxicam—Flatulence—Doxorubicin—prostate cancer	2.14e-05	0.000157	CcSEcCtD
Meloxicam—Tension—Doxorubicin—prostate cancer	2.13e-05	0.000156	CcSEcCtD
Meloxicam—Decreased appetite—Prednisone—prostate cancer	2.13e-05	0.000156	CcSEcCtD
Meloxicam—Dysgeusia—Doxorubicin—prostate cancer	2.13e-05	0.000156	CcSEcCtD
Meloxicam—Malaise—Epirubicin—prostate cancer	2.12e-05	0.000155	CcSEcCtD
Meloxicam—Fatigue—Prednisone—prostate cancer	2.11e-05	0.000155	CcSEcCtD
Meloxicam—Nervousness—Doxorubicin—prostate cancer	2.11e-05	0.000155	CcSEcCtD
Meloxicam—Vertigo—Epirubicin—prostate cancer	2.11e-05	0.000155	CcSEcCtD
Meloxicam—Syncope—Epirubicin—prostate cancer	2.11e-05	0.000154	CcSEcCtD
Meloxicam—Leukopenia—Epirubicin—prostate cancer	2.1e-05	0.000154	CcSEcCtD
Meloxicam—Back pain—Doxorubicin—prostate cancer	2.1e-05	0.000154	CcSEcCtD
Meloxicam—Constipation—Prednisone—prostate cancer	2.1e-05	0.000154	CcSEcCtD
Meloxicam—Hypersensitivity—Docetaxel—prostate cancer	2.1e-05	0.000153	CcSEcCtD
Meloxicam—Muscle spasms—Doxorubicin—prostate cancer	2.09e-05	0.000153	CcSEcCtD
Meloxicam—Palpitations—Epirubicin—prostate cancer	2.08e-05	0.000152	CcSEcCtD
Meloxicam—Loss of consciousness—Epirubicin—prostate cancer	2.07e-05	0.000151	CcSEcCtD
Meloxicam—Cough—Epirubicin—prostate cancer	2.05e-05	0.00015	CcSEcCtD
Meloxicam—Vision blurred—Doxorubicin—prostate cancer	2.05e-05	0.00015	CcSEcCtD
Meloxicam—Asthenia—Docetaxel—prostate cancer	2.04e-05	0.000149	CcSEcCtD
Meloxicam—Convulsion—Epirubicin—prostate cancer	2.04e-05	0.000149	CcSEcCtD
Meloxicam—Nausea—Etoposide—prostate cancer	2.03e-05	0.000149	CcSEcCtD
Meloxicam—Hypertension—Epirubicin—prostate cancer	2.03e-05	0.000149	CcSEcCtD
Meloxicam—Hypersensitivity—Capecitabine—prostate cancer	2.03e-05	0.000148	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisone—prostate cancer	2.02e-05	0.000148	CcSEcCtD
Meloxicam—Ill-defined disorder—Doxorubicin—prostate cancer	2.02e-05	0.000148	CcSEcCtD
Meloxicam—Pruritus—Docetaxel—prostate cancer	2.01e-05	0.000147	CcSEcCtD
Meloxicam—Anaemia—Doxorubicin—prostate cancer	2.01e-05	0.000147	CcSEcCtD
Meloxicam—Gastrointestinal pain—Prednisone—prostate cancer	2.01e-05	0.000147	CcSEcCtD
Meloxicam—Myalgia—Epirubicin—prostate cancer	2e-05	0.000146	CcSEcCtD
Meloxicam—Arthralgia—Epirubicin—prostate cancer	2e-05	0.000146	CcSEcCtD
Meloxicam—Anxiety—Epirubicin—prostate cancer	1.99e-05	0.000146	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.99e-05	0.000145	CcSEcCtD
Meloxicam—Discomfort—Epirubicin—prostate cancer	1.98e-05	0.000145	CcSEcCtD
Meloxicam—Asthenia—Capecitabine—prostate cancer	1.98e-05	0.000145	CcSEcCtD
Meloxicam—Malaise—Doxorubicin—prostate cancer	1.96e-05	0.000144	CcSEcCtD
Meloxicam—Dry mouth—Epirubicin—prostate cancer	1.96e-05	0.000143	CcSEcCtD
Meloxicam—Vertigo—Doxorubicin—prostate cancer	1.95e-05	0.000143	CcSEcCtD
Meloxicam—Syncope—Doxorubicin—prostate cancer	1.95e-05	0.000143	CcSEcCtD
Meloxicam—Urticaria—Prednisone—prostate cancer	1.95e-05	0.000143	CcSEcCtD
Meloxicam—Pruritus—Capecitabine—prostate cancer	1.95e-05	0.000143	CcSEcCtD
Meloxicam—Leukopenia—Doxorubicin—prostate cancer	1.95e-05	0.000142	CcSEcCtD
Meloxicam—Diarrhoea—Docetaxel—prostate cancer	1.95e-05	0.000142	CcSEcCtD
Meloxicam—Abdominal pain—Prednisone—prostate cancer	1.94e-05	0.000142	CcSEcCtD
Meloxicam—Body temperature increased—Prednisone—prostate cancer	1.94e-05	0.000142	CcSEcCtD
Meloxicam—Confusional state—Epirubicin—prostate cancer	1.93e-05	0.000142	CcSEcCtD
Meloxicam—Palpitations—Doxorubicin—prostate cancer	1.92e-05	0.000141	CcSEcCtD
Meloxicam—Oedema—Epirubicin—prostate cancer	1.92e-05	0.00014	CcSEcCtD
Meloxicam—Anaphylactic shock—Epirubicin—prostate cancer	1.92e-05	0.00014	CcSEcCtD
Meloxicam—Loss of consciousness—Doxorubicin—prostate cancer	1.91e-05	0.00014	CcSEcCtD
Meloxicam—Infection—Epirubicin—prostate cancer	1.91e-05	0.000139	CcSEcCtD
Meloxicam—Cough—Doxorubicin—prostate cancer	1.9e-05	0.000139	CcSEcCtD
Meloxicam—Shock—Epirubicin—prostate cancer	1.89e-05	0.000138	CcSEcCtD
Meloxicam—Convulsion—Doxorubicin—prostate cancer	1.88e-05	0.000138	CcSEcCtD
Meloxicam—Diarrhoea—Capecitabine—prostate cancer	1.88e-05	0.000138	CcSEcCtD
Meloxicam—Nervous system disorder—Epirubicin—prostate cancer	1.88e-05	0.000138	CcSEcCtD
Meloxicam—Dizziness—Docetaxel—prostate cancer	1.88e-05	0.000138	CcSEcCtD
Meloxicam—Thrombocytopenia—Epirubicin—prostate cancer	1.88e-05	0.000137	CcSEcCtD
Meloxicam—Hypertension—Doxorubicin—prostate cancer	1.88e-05	0.000137	CcSEcCtD
Meloxicam—Tachycardia—Epirubicin—prostate cancer	1.87e-05	0.000137	CcSEcCtD
Meloxicam—Skin disorder—Epirubicin—prostate cancer	1.86e-05	0.000136	CcSEcCtD
Meloxicam—Hyperhidrosis—Epirubicin—prostate cancer	1.85e-05	0.000136	CcSEcCtD
Meloxicam—Myalgia—Doxorubicin—prostate cancer	1.85e-05	0.000136	CcSEcCtD
Meloxicam—Arthralgia—Doxorubicin—prostate cancer	1.85e-05	0.000136	CcSEcCtD
Meloxicam—Anxiety—Doxorubicin—prostate cancer	1.85e-05	0.000135	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.84e-05	0.000135	CcSEcCtD
Meloxicam—Discomfort—Doxorubicin—prostate cancer	1.83e-05	0.000134	CcSEcCtD
Meloxicam—Dizziness—Capecitabine—prostate cancer	1.82e-05	0.000133	CcSEcCtD
Meloxicam—Dry mouth—Doxorubicin—prostate cancer	1.81e-05	0.000133	CcSEcCtD
Meloxicam—Vomiting—Docetaxel—prostate cancer	1.81e-05	0.000132	CcSEcCtD
Meloxicam—Hypersensitivity—Prednisone—prostate cancer	1.81e-05	0.000132	CcSEcCtD
Meloxicam—Rash—Docetaxel—prostate cancer	1.79e-05	0.000131	CcSEcCtD
Meloxicam—Hypotension—Epirubicin—prostate cancer	1.79e-05	0.000131	CcSEcCtD
Meloxicam—Dermatitis—Docetaxel—prostate cancer	1.79e-05	0.000131	CcSEcCtD
Meloxicam—Confusional state—Doxorubicin—prostate cancer	1.79e-05	0.000131	CcSEcCtD
Meloxicam—Headache—Docetaxel—prostate cancer	1.78e-05	0.00013	CcSEcCtD
Meloxicam—Oedema—Doxorubicin—prostate cancer	1.78e-05	0.00013	CcSEcCtD
Meloxicam—Anaphylactic shock—Doxorubicin—prostate cancer	1.78e-05	0.00013	CcSEcCtD
Meloxicam—Infection—Doxorubicin—prostate cancer	1.76e-05	0.000129	CcSEcCtD
Meloxicam—Asthenia—Prednisone—prostate cancer	1.76e-05	0.000129	CcSEcCtD
Meloxicam—Vomiting—Capecitabine—prostate cancer	1.75e-05	0.000128	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.75e-05	0.000128	CcSEcCtD
Meloxicam—Shock—Doxorubicin—prostate cancer	1.75e-05	0.000128	CcSEcCtD
Meloxicam—Nervous system disorder—Doxorubicin—prostate cancer	1.74e-05	0.000127	CcSEcCtD
Meloxicam—Thrombocytopenia—Doxorubicin—prostate cancer	1.74e-05	0.000127	CcSEcCtD
Meloxicam—Rash—Capecitabine—prostate cancer	1.74e-05	0.000127	CcSEcCtD
Meloxicam—Pruritus—Prednisone—prostate cancer	1.74e-05	0.000127	CcSEcCtD
Meloxicam—Insomnia—Epirubicin—prostate cancer	1.74e-05	0.000127	CcSEcCtD
Meloxicam—Dermatitis—Capecitabine—prostate cancer	1.73e-05	0.000127	CcSEcCtD
Meloxicam—Tachycardia—Doxorubicin—prostate cancer	1.73e-05	0.000127	CcSEcCtD
Meloxicam—Headache—Capecitabine—prostate cancer	1.73e-05	0.000126	CcSEcCtD
Meloxicam—Skin disorder—Doxorubicin—prostate cancer	1.72e-05	0.000126	CcSEcCtD
Meloxicam—Paraesthesia—Epirubicin—prostate cancer	1.72e-05	0.000126	CcSEcCtD
Meloxicam—Hyperhidrosis—Doxorubicin—prostate cancer	1.72e-05	0.000126	CcSEcCtD
Meloxicam—Dyspnoea—Epirubicin—prostate cancer	1.71e-05	0.000125	CcSEcCtD
Meloxicam—Somnolence—Epirubicin—prostate cancer	1.71e-05	0.000125	CcSEcCtD
Meloxicam—Nausea—Docetaxel—prostate cancer	1.69e-05	0.000124	CcSEcCtD
Meloxicam—Dyspepsia—Epirubicin—prostate cancer	1.69e-05	0.000124	CcSEcCtD
Meloxicam—Diarrhoea—Prednisone—prostate cancer	1.68e-05	0.000123	CcSEcCtD
Meloxicam—Decreased appetite—Epirubicin—prostate cancer	1.67e-05	0.000122	CcSEcCtD
Meloxicam—Hypotension—Doxorubicin—prostate cancer	1.66e-05	0.000121	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Epirubicin—prostate cancer	1.66e-05	0.000121	CcSEcCtD
Meloxicam—Fatigue—Epirubicin—prostate cancer	1.65e-05	0.000121	CcSEcCtD
Meloxicam—Constipation—Epirubicin—prostate cancer	1.64e-05	0.00012	CcSEcCtD
Meloxicam—Pain—Epirubicin—prostate cancer	1.64e-05	0.00012	CcSEcCtD
Meloxicam—Nausea—Capecitabine—prostate cancer	1.64e-05	0.00012	CcSEcCtD
Meloxicam—Dizziness—Prednisone—prostate cancer	1.62e-05	0.000119	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.62e-05	0.000118	CcSEcCtD
Meloxicam—Insomnia—Doxorubicin—prostate cancer	1.61e-05	0.000117	CcSEcCtD
Meloxicam—Paraesthesia—Doxorubicin—prostate cancer	1.59e-05	0.000117	CcSEcCtD
Meloxicam—Dyspnoea—Doxorubicin—prostate cancer	1.58e-05	0.000116	CcSEcCtD
Meloxicam—Feeling abnormal—Epirubicin—prostate cancer	1.58e-05	0.000116	CcSEcCtD
Meloxicam—Somnolence—Doxorubicin—prostate cancer	1.58e-05	0.000115	CcSEcCtD
Meloxicam—Gastrointestinal pain—Epirubicin—prostate cancer	1.57e-05	0.000115	CcSEcCtD
Meloxicam—Dyspepsia—Doxorubicin—prostate cancer	1.56e-05	0.000114	CcSEcCtD
Meloxicam—Vomiting—Prednisone—prostate cancer	1.56e-05	0.000114	CcSEcCtD
Meloxicam—Rash—Prednisone—prostate cancer	1.55e-05	0.000113	CcSEcCtD
Meloxicam—Dermatitis—Prednisone—prostate cancer	1.55e-05	0.000113	CcSEcCtD
Meloxicam—Decreased appetite—Doxorubicin—prostate cancer	1.54e-05	0.000113	CcSEcCtD
Meloxicam—Headache—Prednisone—prostate cancer	1.54e-05	0.000112	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.53e-05	0.000112	CcSEcCtD
Meloxicam—Fatigue—Doxorubicin—prostate cancer	1.53e-05	0.000112	CcSEcCtD
Meloxicam—Urticaria—Epirubicin—prostate cancer	1.52e-05	0.000112	CcSEcCtD
Meloxicam—Constipation—Doxorubicin—prostate cancer	1.52e-05	0.000111	CcSEcCtD
Meloxicam—Pain—Doxorubicin—prostate cancer	1.52e-05	0.000111	CcSEcCtD
Meloxicam—Abdominal pain—Epirubicin—prostate cancer	1.52e-05	0.000111	CcSEcCtD
Meloxicam—Body temperature increased—Epirubicin—prostate cancer	1.52e-05	0.000111	CcSEcCtD
Meloxicam—Feeling abnormal—Doxorubicin—prostate cancer	1.46e-05	0.000107	CcSEcCtD
Meloxicam—Nausea—Prednisone—prostate cancer	1.46e-05	0.000107	CcSEcCtD
Meloxicam—Gastrointestinal pain—Doxorubicin—prostate cancer	1.45e-05	0.000106	CcSEcCtD
Meloxicam—Hypersensitivity—Epirubicin—prostate cancer	1.41e-05	0.000103	CcSEcCtD
Meloxicam—Urticaria—Doxorubicin—prostate cancer	1.41e-05	0.000103	CcSEcCtD
Meloxicam—Abdominal pain—Doxorubicin—prostate cancer	1.4e-05	0.000103	CcSEcCtD
Meloxicam—Body temperature increased—Doxorubicin—prostate cancer	1.4e-05	0.000103	CcSEcCtD
Meloxicam—Asthenia—Epirubicin—prostate cancer	1.38e-05	0.000101	CcSEcCtD
Meloxicam—Pruritus—Epirubicin—prostate cancer	1.36e-05	9.93e-05	CcSEcCtD
Meloxicam—Diarrhoea—Epirubicin—prostate cancer	1.31e-05	9.61e-05	CcSEcCtD
Meloxicam—Hypersensitivity—Doxorubicin—prostate cancer	1.31e-05	9.57e-05	CcSEcCtD
Meloxicam—Asthenia—Doxorubicin—prostate cancer	1.27e-05	9.32e-05	CcSEcCtD
Meloxicam—Dizziness—Epirubicin—prostate cancer	1.27e-05	9.28e-05	CcSEcCtD
Meloxicam—Pruritus—Doxorubicin—prostate cancer	1.26e-05	9.19e-05	CcSEcCtD
Meloxicam—Vomiting—Epirubicin—prostate cancer	1.22e-05	8.93e-05	CcSEcCtD
Meloxicam—Diarrhoea—Doxorubicin—prostate cancer	1.21e-05	8.89e-05	CcSEcCtD
Meloxicam—Rash—Epirubicin—prostate cancer	1.21e-05	8.85e-05	CcSEcCtD
Meloxicam—Dermatitis—Epirubicin—prostate cancer	1.21e-05	8.84e-05	CcSEcCtD
Meloxicam—Headache—Epirubicin—prostate cancer	1.2e-05	8.8e-05	CcSEcCtD
Meloxicam—Dizziness—Doxorubicin—prostate cancer	1.17e-05	8.59e-05	CcSEcCtD
Meloxicam—Nausea—Epirubicin—prostate cancer	1.14e-05	8.34e-05	CcSEcCtD
Meloxicam—Vomiting—Doxorubicin—prostate cancer	1.13e-05	8.26e-05	CcSEcCtD
Meloxicam—Rash—Doxorubicin—prostate cancer	1.12e-05	8.19e-05	CcSEcCtD
Meloxicam—Dermatitis—Doxorubicin—prostate cancer	1.12e-05	8.18e-05	CcSEcCtD
Meloxicam—Headache—Doxorubicin—prostate cancer	1.11e-05	8.14e-05	CcSEcCtD
Meloxicam—Nausea—Doxorubicin—prostate cancer	1.05e-05	7.72e-05	CcSEcCtD
Meloxicam—CYP2C8—Metabolism—PRKACB—prostate cancer	3.85e-06	5.22e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	3.82e-06	5.18e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GGT1—prostate cancer	3.81e-06	5.17e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP17A1—prostate cancer	3.81e-06	5.16e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—SULT2A1—prostate cancer	3.76e-06	5.1e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP1A1—prostate cancer	3.76e-06	5.1e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NCOA1—prostate cancer	3.76e-06	5.1e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.75e-06	5.09e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—ERCC2—prostate cancer	3.73e-06	5.06e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP19A1—prostate cancer	3.7e-06	5.02e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—MED12—prostate cancer	3.7e-06	5.02e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—LPL—prostate cancer	3.69e-06	5.01e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ACSL4—prostate cancer	3.67e-06	4.98e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—HSD17B3—prostate cancer	3.67e-06	4.98e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GNG5—prostate cancer	3.67e-06	4.98e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PDGFRB—prostate cancer	3.66e-06	4.96e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NCOA2—prostate cancer	3.63e-06	4.92e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—RXRA—prostate cancer	3.57e-06	4.85e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NCOA3—prostate cancer	3.54e-06	4.8e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERCC2—prostate cancer	3.53e-06	4.8e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ARG2—prostate cancer	3.52e-06	4.78e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PHGDH—prostate cancer	3.52e-06	4.78e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—UMPS—prostate cancer	3.52e-06	4.78e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—MTHFR—prostate cancer	3.5e-06	4.75e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	3.48e-06	4.72e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.47e-06	4.72e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—SLC5A5—prostate cancer	3.46e-06	4.69e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERBB3—prostate cancer	3.46e-06	4.69e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—LDHB—prostate cancer	3.45e-06	4.69e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—FGFR2—prostate cancer	3.45e-06	4.68e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—COMT—prostate cancer	3.44e-06	4.67e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PPARA—prostate cancer	3.44e-06	4.66e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTP1—prostate cancer	3.43e-06	4.65e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP3A5—prostate cancer	3.39e-06	4.6e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP2E1—prostate cancer	3.38e-06	4.59e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—HPGDS—prostate cancer	3.37e-06	4.58e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—ITPR1—prostate cancer	3.37e-06	4.57e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP2C19—prostate cancer	3.35e-06	4.55e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NQO1—prostate cancer	3.34e-06	4.53e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MTHFR—prostate cancer	3.32e-06	4.51e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.31e-06	4.5e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TERT—prostate cancer	3.31e-06	4.49e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—TH—prostate cancer	3.29e-06	4.47e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PDHA1—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTA3—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TCN2—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—UCP3—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTT1—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ACHE—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP3A4—prostate cancer	3.26e-06	4.42e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.24e-06	4.4e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP2A6—prostate cancer	3.23e-06	4.39e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CAV1—prostate cancer	3.23e-06	4.39e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.22e-06	4.37e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP1B1—prostate cancer	3.2e-06	4.35e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—TYMS—prostate cancer	3.18e-06	4.32e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HIF1A—prostate cancer	3.17e-06	4.3e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTM1—prostate cancer	3.15e-06	4.27e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—AKR1C3—prostate cancer	3.15e-06	4.27e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PRKACB—prostate cancer	3.13e-06	4.25e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—HSD3B1—prostate cancer	3.12e-06	4.24e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SLC22A3—prostate cancer	3.12e-06	4.24e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GGT1—prostate cancer	3.1e-06	4.21e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP17A1—prostate cancer	3.1e-06	4.2e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—LPL—prostate cancer	3.09e-06	4.19e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.09e-06	4.19e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CAV1—prostate cancer	3.06e-06	4.16e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NCOA1—prostate cancer	3.06e-06	4.15e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.06e-06	4.15e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP19A1—prostate cancer	3.01e-06	4.09e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTA4—prostate cancer	2.99e-06	4.06e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.99e-06	4.06e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP1A1—prostate cancer	2.98e-06	4.05e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—ERCC2—prostate cancer	2.96e-06	4.02e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NCOA2—prostate cancer	2.95e-06	4.01e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PIK3CG—prostate cancer	2.94e-06	4e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTA2—prostate cancer	2.92e-06	3.96e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—RXRA—prostate cancer	2.91e-06	3.94e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ABCG5—prostate cancer	2.88e-06	3.91e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.88e-06	3.91e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—BAD—prostate cancer	2.88e-06	3.91e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.83e-06	3.84e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.82e-06	3.82e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTA1—prostate cancer	2.81e-06	3.82e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—COMT—prostate cancer	2.8e-06	3.8e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—APC—prostate cancer	2.79e-06	3.79e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTP1—prostate cancer	2.79e-06	3.78e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—INS—prostate cancer	2.79e-06	3.78e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.78e-06	3.78e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTO1—prostate cancer	2.78e-06	3.78e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NAT2—prostate cancer	2.78e-06	3.78e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—MTHFR—prostate cancer	2.78e-06	3.77e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EGF—prostate cancer	2.76e-06	3.74e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—IRS1—prostate cancer	2.76e-06	3.74e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.75e-06	3.73e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—ITPR1—prostate cancer	2.74e-06	3.72e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CREBBP—prostate cancer	2.73e-06	3.7e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PPARA—prostate cancer	2.73e-06	3.7e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NQO1—prostate cancer	2.72e-06	3.69e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.7e-06	3.66e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—TH—prostate cancer	2.68e-06	3.64e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—GSK3B—prostate cancer	2.68e-06	3.63e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—LRP2—prostate cancer	2.67e-06	3.62e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.67e-06	3.62e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PLCB2—prostate cancer	2.67e-06	3.62e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.66e-06	3.61e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.65e-06	3.6e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—INS—prostate cancer	2.64e-06	3.58e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.64e-06	3.58e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—P4HB—prostate cancer	2.62e-06	3.55e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.61e-06	3.54e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—TYMS—prostate cancer	2.59e-06	3.52e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PIK3CD—prostate cancer	2.59e-06	3.51e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CREBBP—prostate cancer	2.59e-06	3.51e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CAV1—prostate cancer	2.57e-06	3.48e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTM1—prostate cancer	2.56e-06	3.48e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.55e-06	3.45e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GGT1—prostate cancer	2.53e-06	3.43e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—LPL—prostate cancer	2.51e-06	3.41e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NCOA1—prostate cancer	2.49e-06	3.38e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.48e-06	3.37e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MAP2K1—prostate cancer	2.47e-06	3.35e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PIK3CD—prostate cancer	2.45e-06	3.33e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.45e-06	3.33e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.45e-06	3.33e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NOS3—prostate cancer	2.44e-06	3.32e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—MED12—prostate cancer	2.44e-06	3.31e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP1A1—prostate cancer	2.43e-06	3.29e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—SERPINE1—prostate cancer	2.43e-06	3.29e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GNG5—prostate cancer	2.42e-06	3.29e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—ERCC2—prostate cancer	2.41e-06	3.27e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—RXRA—prostate cancer	2.37e-06	3.21e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—FGF2—prostate cancer	2.35e-06	3.19e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PIK3CG—prostate cancer	2.34e-06	3.17e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NCOA3—prostate cancer	2.33e-06	3.17e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—NOS3—prostate cancer	2.32e-06	3.14e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.3e-06	3.12e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—COMT—prostate cancer	2.28e-06	3.09e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTP1—prostate cancer	2.27e-06	3.08e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—MTHFR—prostate cancer	2.26e-06	3.07e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PIK3CB—prostate cancer	2.26e-06	3.06e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—JAK2—prostate cancer	2.25e-06	3.06e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTGS2—prostate cancer	2.24e-06	3.03e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ITPR1—prostate cancer	2.23e-06	3.03e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—HPGDS—prostate cancer	2.22e-06	3.02e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PPARA—prostate cancer	2.22e-06	3.01e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—INS—prostate cancer	2.21e-06	3e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.21e-06	3e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MDM2—prostate cancer	2.2e-06	2.98e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.19e-06	2.98e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CREBBP—prostate cancer	2.17e-06	2.94e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERBB2—prostate cancer	2.17e-06	2.94e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTT1—prostate cancer	2.16e-06	2.93e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ACHE—prostate cancer	2.16e-06	2.93e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PIK3CB—prostate cancer	2.14e-06	2.9e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.13e-06	2.89e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—TYMS—prostate cancer	2.11e-06	2.86e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CAV1—prostate cancer	2.09e-06	2.83e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTM1—prostate cancer	2.08e-06	2.83e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.08e-06	2.82e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PRKACB—prostate cancer	2.06e-06	2.8e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PIK3CD—prostate cancer	2.05e-06	2.79e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—LPL—prostate cancer	2.05e-06	2.78e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.04e-06	2.77e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CDKN1B—prostate cancer	2.01e-06	2.72e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.99e-06	2.71e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.98e-06	2.68e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ERCC2—prostate cancer	1.96e-06	2.66e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTEN—prostate cancer	1.95e-06	2.65e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NCOA2—prostate cancer	1.95e-06	2.64e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NOS3—prostate cancer	1.94e-06	2.63e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.9e-06	2.58e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CTNNB1—prostate cancer	1.9e-06	2.57e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—EP300—prostate cancer	1.86e-06	2.52e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.86e-06	2.52e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CDKN1A—prostate cancer	1.85e-06	2.51e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PTEN—prostate cancer	1.85e-06	2.51e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—MTHFR—prostate cancer	1.84e-06	2.5e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.81e-06	2.46e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PPARA—prostate cancer	1.81e-06	2.45e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—INS—prostate cancer	1.8e-06	2.44e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NQO1—prostate cancer	1.79e-06	2.43e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PIK3CB—prostate cancer	1.79e-06	2.43e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TH—prostate cancer	1.77e-06	2.4e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CREBBP—prostate cancer	1.76e-06	2.39e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EP300—prostate cancer	1.76e-06	2.39e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.72e-06	2.33e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—SRC—prostate cancer	1.71e-06	2.33e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CAV1—prostate cancer	1.7e-06	2.31e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.67e-06	2.27e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GGT1—prostate cancer	1.67e-06	2.26e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—STAT3—prostate cancer	1.65e-06	2.24e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NCOA1—prostate cancer	1.64e-06	2.23e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.62e-06	2.2e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.62e-06	2.19e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NOS3—prostate cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—RXRA—prostate cancer	1.56e-06	2.12e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.55e-06	2.1e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PTEN—prostate cancer	1.55e-06	2.1e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MYC—prostate cancer	1.54e-06	2.08e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TGFB1—prostate cancer	1.53e-06	2.08e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—COMT—prostate cancer	1.5e-06	2.04e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EGFR—prostate cancer	1.5e-06	2.04e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTP1—prostate cancer	1.5e-06	2.03e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—EP300—prostate cancer	1.48e-06	2e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ITPR1—prostate cancer	1.47e-06	2e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—INS—prostate cancer	1.47e-06	1.99e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.46e-06	1.98e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTGS2—prostate cancer	1.44e-06	1.96e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CREBBP—prostate cancer	1.43e-06	1.95e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—KRAS—prostate cancer	1.42e-06	1.93e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TYMS—prostate cancer	1.39e-06	1.89e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PIK3CA—prostate cancer	1.38e-06	1.87e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTM1—prostate cancer	1.37e-06	1.87e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.36e-06	1.85e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—LPL—prostate cancer	1.35e-06	1.83e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PIK3CA—prostate cancer	1.3e-06	1.77e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.3e-06	1.77e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ERCC2—prostate cancer	1.29e-06	1.75e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NOS3—prostate cancer	1.28e-06	1.74e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTEN—prostate cancer	1.26e-06	1.71e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—MTHFR—prostate cancer	1.21e-06	1.65e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—EP300—prostate cancer	1.2e-06	1.63e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PPARA—prostate cancer	1.19e-06	1.62e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.19e-06	1.61e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTGS2—prostate cancer	1.18e-06	1.59e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—IL6—prostate cancer	1.15e-06	1.57e-05	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—AKT1—prostate cancer	1.12e-06	1.52e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CAV1—prostate cancer	1.12e-06	1.52e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PIK3CA—prostate cancer	1.09e-06	1.48e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—AKT1—prostate cancer	1.06e-06	1.45e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTEN—prostate cancer	1.02e-06	1.39e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.02e-06	1.39e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—EP300—prostate cancer	9.77e-07	1.33e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—INS—prostate cancer	9.66e-07	1.31e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CREBBP—prostate cancer	9.46e-07	1.28e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PIK3CD—prostate cancer	8.97e-07	1.22e-05	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—AKT1—prostate cancer	8.92e-07	1.21e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PIK3CA—prostate cancer	8.88e-07	1.21e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NOS3—prostate cancer	8.47e-07	1.15e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PIK3CB—prostate cancer	7.82e-07	1.06e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTGS2—prostate cancer	7.75e-07	1.05e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—AKT1—prostate cancer	7.26e-07	9.85e-06	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PIK3CA—prostate cancer	7.23e-07	9.81e-06	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTEN—prostate cancer	6.76e-07	9.17e-06	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—EP300—prostate cancer	6.45e-07	8.75e-06	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—AKT1—prostate cancer	5.91e-07	8.01e-06	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.77e-07	6.47e-06	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—AKT1—prostate cancer	3.89e-07	5.29e-06	CbGpPWpGaD
